IRADIMED Resultados de beneficios anteriores
Pasado controles de criterios 5/6
IRADIMED ha aumentado sus beneficios a una tasa media anual de 25.4%, mientras que los beneficios de la industria de Medical Equipment han experimentado un crecimiento de 14.8% anual. Los ingresos han ido creciendo a una tasa media de 17.4% al año. La rentabilidad financiera de IRADIMED es de 24%, y sus márgenes netos son de 27.4%.
Información clave
25.38%
Tasa de crecimiento de los beneficios
24.88%
Tasa de crecimiento del BPA
| Crecimiento de la industria Medical Equipment | 8.90% |
| Tasa de crecimiento de los ingresos | 17.40% |
| Rentabilidad financiera | 23.97% |
| Margen neto | 27.36% |
| Última actualización de beneficios | 31 Mar 2026 |
Actualizaciones de resultados anteriores recientes
Recent updates
Actualización de narrativa • Jun 04
IRMD: 2026 Guidance And Bullish Coverage Will Support Further Re Rating
Analysts have nudged their price target on IRADIMED slightly lower, from about $118.67 to $118.00. They are refining assumptions around discount rates, revenue growth, margins and future P/E expectations following recent bullish Street coverage.Actualización de narrativa • Apr 30
IRMD: 2026 Dividend And Guidance Will Anchor Bullish Re Rating
Analysts nudged their price targets for IRADIMED higher, with recent Street research citing supportive views on the business. These views help explain the updated fair value of $118.67 along with a slightly adjusted discount rate and forward P/E assumptions.Actualización de narrativa • Apr 12
IRMD: 2026 Dividend And Guidance Will Support Bullish Re-Rating
Analysts have trimmed their fair value estimate for IRADIMED from about $120 to roughly $118.67, citing revised assumptions for revenue growth, profit margins and future P/E. At the same time, recent Street research, including fresh bullish initiations and higher price targets, continues to support a constructive view on the stock.Actualización de narrativa • Mar 26
IRMD: 2026 Guidance And Dividend Will Support Higher Price Re-Rating
Analysts have lifted their price target on IRADIMED by a double digit dollar amount, citing updated valuation work that reflects refined assumptions, including a fair value of $120, a discount rate of 7.69%, revenue growth of 9.70%, a profit margin of 27.77% and a future P/E of 58.53. Analyst Commentary Recent research points to a tighter alignment between IRADIMED's valuation work and updated assumptions on growth, profitability and the P/E investors may be willing to pay.Actualización de narrativa • Mar 11
IRMD: 2026 Guidance And Dividend Will Support Higher P/E Repricing
Narrative Update on IRADIMED The analyst price target on IRADIMED has been raised by $20 to $120. Analysts cite updated valuation work that incorporates a slightly higher discount rate and future P/E assumption, along with recent Street research that supports the new level.Actualización de narrativa • Feb 25
IRMD: 2026 Guidance And Dividends Will Support Higher Earnings Multiple
Analysts have lifted their fair value estimate for IRADIMED from $99 to $120, citing updated assumptions around slightly different revenue growth, profit margin expectations, discount rate, and a higher future P/E. These revisions align with recent Street price target increases reported by firms such as Lake Street and Roth Capital.Actualización de narrativa • Feb 10
IRMD: Stable Outlook Will Rely On 2026 Guidance And Dividend Support
Analysts have kept their price target for IRADIMED effectively unchanged at $99.00. They cite only marginal tweaks to discount rate, revenue growth, profit margin, and future P/E assumptions rather than any shift in their core view on the company.Actualización de narrativa • Jan 27
IRMD: Record Backlog And Raised Guidance Will Support Premium Yet Balanced Outlook
Narrative Update Analysts have nudged their price targets for IRADIMED higher into a US$98 to US$100 range, reflecting updated forward estimates, a record backlog, the recent beat and raise quarter, and expectations tied to the 3870 IV Pump launch. Analyst Commentary Analysts updating their models for IRADIMED are broadly constructive, with recent research focused on how the latest quarter and product pipeline translate into earnings power and valuation support.Actualización de narrativa • Jan 12
IRMD: Raised Guidance And Backlog Support Premium While Risks Keep Outlook Balanced
Narrative Update Introduction Analysts have lifted their price expectations for IRADIMED to a range of about $98 to $100, citing higher forward estimates, a record backlog that supports near term visibility, and confidence around the 3870 IV Pump launch as key reasons for the updated targets. Analyst Commentary Recent Street research on IRADIMED reflects a clear tilt toward optimism, with price targets lifted into the high double digits following the latest quarterly update.Actualización de narrativa • Dec 14
IRMD: Raised Guidance And Backlog Will Support Premium Amid Execution Risks
Analysts have nudged their average price target on IRADIMED higher, to a level just under $100 per share from the low $90s, citing stronger than expected Q3 results, raised full year guidance, and growing confidence that a robust backlog and upcoming product launches will support sustained growth. Analyst Commentary Bullish analysts highlight that the recent upside surprise on both revenue and earnings, along with raised full year guidance, reinforces a view that IRADIMED is executing ahead of prior expectations and can support a higher valuation multiple.Actualización de narrativa • Nov 29
IRMD: Raised Guidance And Strong Backlog Will Maintain Premium Despite Execution Risks
IRADIMED’s analyst price target has been raised from $90 to a range approaching $100 per share. Analysts cite the company’s recent sales and earnings outperformance, increased full-year guidance, and strong prospects from product innovation and backlog growth.Actualización de narrativa • Nov 15
IRMD: Raised Guidance And Record Backlog Are Set To Drive Continued Momentum
Analysts have raised their price target for IRADIMED significantly, from $82.50 to $99.00. They cited stronger-than-expected quarterly results, improved guidance, and a robust outlook driven by a growing backlog and product innovation.Actualización de narrativa • Nov 01
IRMD: Index Addition and Strong Margins Will Support Measured Upside
Analysts have raised their price target for IRADIMED from $73.50 to $82.50. They cite modest improvements in projected profit margins and valuation multiples as key drivers behind the adjustment.Artículo de análisis • Oct 09
Should You Be Adding IRADIMED (NASDAQ:IRMD) To Your Watchlist Today?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Artículo de análisis • Aug 13
IRADIMED CORPORATION's (NASDAQ:IRMD) Shares Climb 27% But Its Business Is Yet to Catch Up
Despite an already strong run, IRADIMED CORPORATION ( NASDAQ:IRMD ) shares have been powering on, with a gain of 27% in...Artículo de análisis • Aug 08
IRADIMED's (NASDAQ:IRMD) Profits May Not Reveal Underlying Issues
NasdaqGM:IRMD 1 Year Share Price vs Fair Value Explore IRADIMED's Fair Values from the Community and select yours The...Artículo de análisis • Jun 01
Shareholders Would Enjoy A Repeat Of IRADIMED's (NASDAQ:IRMD) Recent Growth In Returns
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
Nueva narrativa • Sep 24
Innovative IV Pumps And Monitor Expansion Set To Spearhead Revenue Surge And Enhance Profit Margins
Introduction of the new 3870 IV pump and expansion in the Monitor business signal potential significant revenue growth and increases in product line revenue.Artículo de análisis • Aug 08
IRADIMED's (NASDAQ:IRMD) Solid Profits Have Weak Fundamentals
Despite announcing strong earnings, IRADIMED CORPORATION's ( NASDAQ:IRMD ) stock was sluggish. Our analysis uncovered...Artículo de análisis • Feb 23
If EPS Growth Is Important To You, IRadimed (NASDAQ:IRMD) Presents An Opportunity
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Artículo de análisis • Feb 07
Getting In Cheap On IRadimed Corporation (NASDAQ:IRMD) Is Unlikely
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 16x, you may...Artículo de análisis • Nov 06
Should You Investigate IRadimed Corporation (NASDAQ:IRMD) At US$45.06?
While IRadimed Corporation ( NASDAQ:IRMD ) might not be the most widely known stock at the moment, it led the NASDAQCM...Artículo de análisis • Oct 13
Calculating The Intrinsic Value Of IRadimed Corporation (NASDAQ:IRMD)
Key Insights Using the 2 Stage Free Cash Flow to Equity, IRadimed fair value estimate is US$36.84 IRadimed's US$37.31...Artículo de análisis • Feb 05
At US$41.26, Is It Time To Put IRadimed Corporation (NASDAQ:IRMD) On Your Watch List?
While IRadimed Corporation ( NASDAQ:IRMD ) might not be the most widely known stock at the moment, it led the NASDAQCM...Desglose de ingresos y gastos
Desglose de ingresos y gastos
Cómo gana y gasta dinero IRADIMED. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 31 Mar 26 | 86 | 24 | 35 | 3 |
| 31 Dec 25 | 84 | 22 | 35 | 3 |
| 30 Sep 25 | 81 | 21 | 34 | 3 |
| 30 Jun 25 | 78 | 21 | 33 | 3 |
| 31 Mar 25 | 75 | 20 | 33 | 3 |
| 31 Dec 24 | 73 | 19 | 32 | 3 |
| 30 Sep 24 | 71 | 19 | 31 | 3 |
| 30 Jun 24 | 69 | 19 | 30 | 3 |
| 31 Mar 24 | 68 | 18 | 28 | 3 |
| 31 Dec 23 | 66 | 17 | 27 | 3 |
| 30 Sep 23 | 63 | 16 | 26 | 3 |
| 30 Jun 23 | 60 | 15 | 25 | 3 |
| 31 Mar 23 | 56 | 14 | 25 | 3 |
| 31 Dec 22 | 53 | 13 | 23 | 2 |
| 30 Sep 22 | 50 | 13 | 23 | 2 |
| 30 Jun 22 | 48 | 12 | 22 | 2 |
| 31 Mar 22 | 45 | 10 | 21 | 2 |
| 31 Dec 21 | 42 | 9 | 20 | 2 |
| 30 Sep 21 | 38 | 6 | 17 | 2 |
| 30 Jun 21 | 35 | 5 | 17 | 2 |
| 31 Mar 21 | 32 | 1 | 19 | 2 |
| 31 Dec 20 | 32 | 1 | 20 | 2 |
| 30 Sep 20 | 34 | 4 | 23 | 2 |
| 30 Jun 20 | 36 | 5 | 23 | 2 |
| 31 Mar 20 | 39 | 10 | 20 | 1 |
| 31 Dec 19 | 39 | 10 | 20 | 1 |
| 30 Sep 19 | 36 | 8 | 18 | 1 |
| 30 Jun 19 | 34 | 8 | 17 | 1 |
| 31 Mar 19 | 32 | 7 | 16 | 1 |
| 31 Dec 18 | 30 | 6 | 16 | 2 |
| 30 Sep 18 | 29 | 5 | 15 | 1 |
| 30 Jun 18 | 27 | 3 | 15 | 2 |
| 31 Mar 18 | 25 | 2 | 15 | 2 |
| 31 Dec 17 | 23 | 0 | 15 | 2 |
| 30 Sep 17 | 22 | 1 | 14 | 2 |
| 30 Jun 17 | 24 | 3 | 13 | 2 |
| 31 Mar 17 | 29 | 5 | 14 | 2 |
| 31 Dec 16 | 32 | 7 | 14 | 1 |
| 30 Sep 16 | 35 | 8 | 15 | 1 |
| 30 Jun 16 | 35 | 9 | 14 | 2 |
| 31 Mar 16 | 33 | 8 | 13 | 2 |
| 31 Dec 15 | 31 | 8 | 12 | 2 |
| 30 Sep 15 | 26 | 5 | 11 | 2 |
| 30 Jun 15 | 22 | 4 | 10 | 1 |
Ingresos de calidad: IRMD tiene ganancias de alta calidad.
Margen de beneficios creciente: Los actuales márgenes de beneficio (27.4%) de IRMD son superiores a los del año pasado (26.3%).
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: En los últimos 5 años, los beneficios de lIRMD han crecido significativamente en un 25.4% al año.
Acelerando crecimiento: El crecimiento de los beneficios de IRMD en el último año (19.3%) está por debajo de su media de 5 años (25.4% al año).
Beneficios vs. Industria: El crecimiento de los beneficios de IRMD en el último año (19.3%) superó al de la industria Medical Equipment 15.7%.
Rentabilidad financiera
Alta ROE: La rentabilidad financiera (24%) de IRMD se considera alta.
Rentabilidad económica
Rendimiento del capital invertido
Descubre empresas con buenos resultados en el pasado
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/06/09 19:59 |
| Precio de las acciones al final del día | 2026/06/09 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
IRADIMED CORPORATION está cubierta por 4 analistas. 2 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Lawrence Solow | CJS Securities, Inc. |
| Ilya Zubkov | Freedom Broker |
| Frank Takkinen | Lake Street Capital Markets, LLC |